首页> 美国卫生研究院文献>BMJ Open Access >Original article: The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon
【2h】

Original article: The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon

机译:原始文章:ATG16L1中的Thr300Ala变体与人类结直肠癌的生存改善和I型干扰素产生的增加有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveATG16L1 is an autophagy gene known to control host immune responses to viruses and bacteria. Recently, a non-synonymous single-nucleotide polymorphism in ATG16L1 (Thr300Ala), previously identified as a risk factor in Crohn's disease (CD), was associated with more favourable clinical outcomes in thyroid cancer. Mechanisms underlying this observation have not been proposed, nor is it clear whether an association between Thr300Ala and clinical outcomes will be observed in other cancers. We hypothesised that Thr300Ala influences clinical outcome in human colorectal cancer (CRC) and controls innate antiviral pathways in colon cancer cells.
机译:ObjectiveATG16L1是一种自噬基因,已知可以控制宿主对病毒和细菌的免疫反应。最近,先前被确定为克罗恩病(CD)的危险因素的ATG16L1(Thr300Ala)中的非同义单核苷酸多态性与甲状腺癌的更佳临床预后相关。还没有提出这种观察的基础机制,也不清楚在其他癌症中是否会观察到Thr300Ala与临床结果之间的关联。我们假设Thr300Ala影响人结肠直肠癌(CRC)的临床结果并控制结肠癌细胞中的先天抗病毒途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号